NextCure stock, Avere merger

NextCure stock: Avere merger advances with 820 million US dollars

Published on 11/19/2026 at 04:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
NextCure advances its proposed Avere merger. NextCure stock faces a December 9 shareholder vote as closing remains subject to approval.

Merger financing and next steps

  • NextCure reported a third-quarter net loss of 6.846 million US dollars, down from 8.624 million US dollars a year earlier.
  • Cash, cash equivalents and marketable securities totaled 8.728 million US dollars at September 30, 2026.
  • The proposed transaction would create Avere, subject to stockholder approval and other closing conditions.
NextCure stock, Avere merger, biotechnology, quarterly results, financing, shareholder vote, Illustration mit AI erstellt.

NextCure said on November 10, 2026, that its proposed merger with Avere Therapeutics is moving toward a stockholder vote, while the transaction remains subject to approval and other closing conditions. The company reported the update alongside results for the quarter ended September 30. The NextCure news release said financing commitments supporting the proposed merger had reached 820 million US dollars.

Vote set for December 9

The financing consists of a previously announced 320 million US dollar concurrent private placement and an additional 500 million US dollar private placement. Approximately 266 million US dollars of the additional financing is expected to be satisfied through the contribution and cancellation of Avere convertible notes.

NextCure said the Securities and Exchange Commission declared the merger registration statement effective on November 6, 2026. The company established November 3 as the record date and scheduled a special meeting for December 9 at 9:00 a.m. Eastern Time. If approved and completed, the combined company is expected to operate as Avere and trade on Nasdaq under the symbol AVRX. Existing NextCure stockholders are expected to retain a minority ownership interest and receive contingent value rights tied to specified legacy assets.

Quarterly loss narrows

Net loss for the third quarter was 6.846 million US dollars, compared with 8.624 million US dollars in the year-earlier quarter. Research and development expenses declined to 4.535 million US dollars from 6.136 million US dollars, while general and administrative expenses rose to 4.428 million US dollars from 2.809 million US dollars.

NextCure also reported 8.728 million US dollars in cash, cash equivalents and marketable securities at September 30, compared with 41.818 million US dollars at December 31, 2025. Restructuring and asset impairment charges, net were a gain of 2.044 million US dollars in the quarter, including lease termination and asset sale gains partly offset by severance costs.

Legacy assets remain in focus

NextCure is a biopharmaceutical company managing legacy clinical and intellectual property assets while pursuing licensing, partnering and other ways to derive value from them. Its disclosed programs include LNCB74 and SIM0505, while the proposed Avere combination would advance Avere's oral IL-23 program AVR-001. The company is based in Beltsville, Maryland, in the United States.

NextCure at a glance

  • Company: NextCure, Inc.
  • Ticker: NXTC
  • Exchange: Nasdaq Global Select Market
  • Quarter: Three months ended September 30, 2026
  • Net loss: 6.846 million US dollars
  • Cash, cash equivalents and marketable securities: 8.728 million US dollars at September 30, 2026

The US market backdrop is covered in the S&P 500 market overview.

More market context is available in the current market reports.

Disclaimer...
en | boerse | 70533516 |